神经母细胞瘤
化疗
生物
微小残留病
癌症研究
多药耐受
细胞
疾病
生物信息学
医学
遗传学
内科学
细胞培养
白血病
生物膜
细菌
作者
Liron D. Grossmann,Chia-Hui Chen,Yasin Uzun,Anusha Thadi,Adam J. Wolpaw,Kévin Louault,Yael Goldstein,Lea F. Surrey,Daniel Martínez,Matteo Calafatti,Mark Gerelus,Peng Gao,Lobin Lee,Khushbu Patel,Rebecca Kaufman,Guy Shani,Alvin Farrel,Sharon Moshitch-Moshkovitz,Paris Grimaldi,Matthew Shapiro
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2024-07-31
卷期号:14 (12): 2387-2406
被引量:18
标识
DOI:10.1158/2159-8290.cd-24-0046
摘要
Abstract Relapse rates in high-risk neuroblastoma remain exceedingly high. The malignant cells that are responsible for relapse have not been identified, and mechanisms of therapy resistance remain poorly understood. In this study, we used single-nucleus RNA sequencing and bulk whole-genome sequencing to identify and characterize the residual malignant persister cells that survive chemotherapy from a cohort of 20 matched diagnosis and definitive surgery tumor samples from patients treated with high-risk neuroblastoma induction chemotherapy. We show that persister cells share common mechanisms of chemotherapy escape, including suppression of MYC(N) activity and activation of NFκB signaling, and the latter is further enhanced by cell–cell communication between the malignant cells and the tumor microenvironment. Overall, our work dissects the transcriptional landscape of cellular persistence in high-risk neuroblastoma and paves the way to the development of new therapeutic strategies to prevent disease relapse. Significance: Approximately 50% of patients with high-risk neuroblastoma die of relapsed refractory disease. We identified the malignant cells that likely contribute to relapse and discovered key signaling pathways that mediate cellular persistence. Inhibition of these pathways and their downstream effectors is postulated to eliminate persister cells and prevent relapse. See related commentary by Wolf et al., p. 2308
科研通智能强力驱动
Strongly Powered by AbleSci AI